Post-exposure prophylaxis (PEP) can prevent death due to rabies infection. For every patient not previously vaccinated against rabies, PEP must include wound cleansing, passive immunization with human rabies immune globulin (HRIG), and administration of rabies vaccine.1


Post-exposure prophylaxis consists of a single dose of KEDRAB and a full course of rabies vaccine. The recommended dose of KEDRAB is 20 IU/kg body weight, given at the time of the first vaccine dose. KEDRAB and the first dose of rabies vaccine should be given as soon as possible after exposure, as delays are potentially lethal. However, should a delay occur, KEDRAB should be administered at any time up to and including seven days after the first dose of vaccine. The rabies vaccine should be given according to the manufacturer’s instructions.2


No more than the recommended dose of KEDRAB should be given because KEDRAB partially suppresses active antibody production following vaccination. For the same reason, additional doses of KEDRAB should not be given, even if the antibody response to vaccination is delayed.2


KEDRAB is for wound infiltration and intramuscular use. Do not administer intravenously. Do not mix with the rabies vaccine or administer in the same syringe with the rabies vaccine. Do not administer into the same anatomical site(s) as rabies vaccine. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. If either of these conditions exists, DO NOT use KEDRAB; contact Kedrion Biopharma Customer Service.2

  • Avoid administration into the gluteal region, where absorbance is unpredictable (unless the exposure site is in the gluteal region)
  • If a large intramuscular volume is required (>2 mL for children or >5 mL for adults), administer the total volume in divided doses at different sites
  • If intramuscular administration is contraindicated (eg, in patients with uncorrectable bleeding disorders), administer KEDRAB subcutaneously. However, note that there are no clinical efficacy data to support administration of KEDRAB by the subcutaneous route

Known Bite Site

When the bite site is known and infiltration at the bite site is feasible2:

  • Infiltrate as much of the dose as possible into and around any detectable bite wounds. Inject any remaining volume intramuscularly into the upper arm deltoid region or, in small children, into the anterolateral aspect of the thigh. Administer the remaining KEDRAB at site(s) distant from the site of the rabies vaccine


Unknown or Indeterminate Bite Site

When the bite site is unknown or indeterminate (undetectable) or if infiltration is difficult at the bite site (eg, lips, fingers, knee)2:

  • Administer the full KEDRAB dose by the intramuscular route at a site distant from the site of rabies vaccination


Supplied in Two Vial Sizes2

2-mL vial

The 2-mL vial contains a total of 300 IU, which is sufficient for a child weighing 15 kg (33 lb).

NDC 76125-150-02

10-mL vial

The 10-mL vial contains a total of 1500 IU, which is sufficient for an adult weighing 75 kg (165 lb).

NDC 76125-150-10

Each carton of KEDRAB contains a single-use vial containing 2 mL or 10 mL of ready-to-use solution with a nominal potency of 150 IU/mL.

Product Storage2

Store KEDRAB at
2-8°C (36-46°F). Do not freeze.

Keep vial in carton until use.

KEDRAB may be stored at room temperature not exceeding 25°C (77°F) for up to one month.

Use within one month after removal from refrigeration. Do not return to refrigeration.

Do not use after the expiration date printed on the label.

Enroll for Rabies Updates

If you are interested in receiving the most current information about KEDRAB HRIG, proper PEP, and the rabies virus (RABV), as well as educational rabies resources, enroll now.